PHAT Stock Price, Phathom Pharmaceuticals Quote, Chart

Market Summary

USD10.56-0.13

Market Closed

-1.22%

PHAT Stock Price

View Fullscreen

PHAT RSI Chart

PHAT Valuation

Market Cap

618.1M

Price/Earnings (Trailing)

-2.51

Price/Sales (Trailing)

906.35

Price/Free Cashflow

-3.67

PHAT Price/Sales (Trailing)

PHAT Profitability

Operating Margin

75.51%

Return on Equity

166.08%

Return on Assets

-69.18%

Free Cashflow Yield

-27.24%

PHAT Fundamentals

PHAT Revenue

Revenue (TTM)

682.0K

PHAT Earnings

Earnings (TTM)

-246.6M

Earnings Growth (Yr)

-119.1%

Earnings Growth (Qtr)

-4.12%

Breaking Down PHAT Revenue

Last 7 days

10.9%

Last 30 days

7.8%

Last 90 days

13.7%

Trailing 12 Months

-18.4%

How does PHAT drawdown profile look like?

PHAT Financial Health

Current Ratio

7.83

Debt/Equity

-1

Debt/Cashflow

-1.12

PHAT Investor Care

Shares Dilution (1Y)

34.21%

Diluted EPS (TTM)

-4.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	682.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Phathom Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	henderson molly	sold	-38,128	11.1	-3,435	cfo and cbo
Mar 22, 2024	curran terrie	sold	-153,513	9.11	-16,851	president and chief executive
Jan 24, 2024	takeda pharmaceutical co ltd	sold	-30,000,000	8.1	-3,703,700	-
Jan 19, 2024	henderson molly	sold	-48,900	7.7533	-6,307	cfo and cbo
Nov 20, 2023	henderson molly	sold	-15,402	7.2415	-2,127	cfo and cbo
Nov 08, 2023	parikh asit	bought	19,500	7.8	2,500	-
Nov 07, 2023	parikh asit	bought	31,040	7.76	4,000	-
Nov 06, 2023	parikh asit	bought	8,040	8.04	1,000	-
Nov 01, 2023	henderson molly	acquired	-	-	22,500	cfo and cbo
Nov 01, 2023	nabulsi azmi	acquired	-	-	32,500	chief operating officer

Which funds bought or sold PHAT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.37	28,130	307,417	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-61.66	-330,046	265,723	-%
May 15, 2024	Octagon Capital Advisors LP	added	810	4,375,600	4,832,100	0.58%
May 15, 2024	Saturn V Capital Management LP	added	212	3,859,000	5,320,480	2.13%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	29.42	377,410	1,124,180	-%
May 15, 2024	BARCLAYS PLC	reduced	-43.23	-154,000	300,000	-%
May 15, 2024	Checkpoint Capital L.P.	added	23.85	1,445,870	4,727,610	3.16%
May 15, 2024	Frazier Life Sciences Management, L.P.	unchanged	-	15,062,800	107,361,000	4.53%
May 15, 2024	Ghost Tree Capital, LLC	added	25.9	1,633,450	5,150,700	1.43%
May 15, 2024	Virtus ETF Advisers LLC	reduced	-6.42	8,374	103,025	0.06%

Are Funds Buying or Selling PHAT?

Are funds buying PHAT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PHAT

No. of Funds

Unveiling Phathom Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	takeda pharmaceutical co ltd	4.8%	2,790,480	SC 13D/A
Apr 01, 2024	takeda pharmaceutical co ltd	5.4%	3,153,217	SC 13D/A
Feb 12, 2024	carlyle group inc.	6.1%	3,496,808	SC 13G/A
Feb 09, 2024	invesco ltd.	5.5%	3,167,653	SC 13G/A
Jan 26, 2024	medicxi growth i lp	6.4%	3,673,602	SC 13G/A
Jan 25, 2024	takeda pharmaceutical co ltd	6.6%	3,755,583	SC 13D/A
May 26, 2023	frazier life sciences public fund, l.p.	10.7%	5,827,415	SC 13D/A
May 05, 2023	frazier life sciences public fund, l.p.	13.4%	5,827,415	SC 13D/A
Mar 09, 2023	carlyle group inc.	6.7%	2,935,106	SC 13G
Feb 14, 2023	avidity partners management lp	4.6%	1,900,000	SC 13G/A

Recent SEC filings of Phathom Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 12, 2024	DEFA14A	DEFA14A
Apr 12, 2024	DEF 14A	DEF 14A
Apr 12, 2024	ARS	ARS
Apr 10, 2024	SC 13D/A	13D - Major Acquisition
Apr 10, 2024	4	Insider Trading
Apr 01, 2024	SC 13D/A	13D - Major Acquisition
Mar 26, 2024	4	Insider Trading
Mar 07, 2024	8-K	Current Report

Peers (Alternatives to Phathom Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Phathom Pharmaceuticals Inc News

Latest updates

Phathom Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1
Revenue	-	1,912	-	-
Cost Of Revenue	-	426	-	-
Gross Profit	-	1,486	-	-
Operating Expenses	1.5%	71,440	70,390	30,077
S&GA Expenses	8.8%	62,010	56,997	18,598
R&D Expenses	-29.6%	9,430	13,394	11,479
Interest Expenses	31.8%	17,168	13,029	9,217
Net Income	-4.1%	-82,852	-79,570	-37,814
Net Income Margin	-22.3%	-361.63*	-295.59*	-
Free Cashflow	-56.0%	-69,060	-44,272	-39,883

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-13.9%	356	414	237	265	144	165	202	214	149	189	228	215	246	295	231	252	264	257	80.00	-
Current Assets	-14.4%	340	397	227	258	140	161	198	209	146	187	225	211	243	291	227	249	262	256	78.00	1.00
Cash Equivalents	-15.5%	322	381	214	249	130	155	197	207	138	183	225	210	238	287	226	247	257	244	74.00	1.00
Inventory	20.7%	1.00	1.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-8.6%	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	-
Liabilities	3.8%	505	487	255	247	234	240	228	221	111	117	125	82.00	82.00	101	75.00	64.00	55.00	29.00	232	-
Current Liabilities	12.1%	43.00	39.00	24.00	22.00	14.00	26.00	23.00	21.00	11.00	19.00	28.00	40.00	41.00	56.00	28.00	13.00	5.00	4.00	207	2.00
Long Term Debt	8.1%	149	138	99.00	98.00	97.00	95.00	94.00	92.00	91.00	90.00	88.00	37.00	36.00	40.00	41.00	45.00	46.00	23.00	23.00	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	10.00	12.00	7.00	6.00	1.00	-	-	-	-
LT Debt, Non Current	-100.0%	-	138	99.00	98.00	97.00	95.00	94.00	92.00	91.00	90.00	88.00	37.00	36.00	40.00	41.00	45.00	-	23.00	-	-
Shareholder's Equity	-104.1%	-148	-72.76	-	18.00	-90.19	-74.81	-	-	38.00	72.00	103	132	164	194	156	188	209	228	-	-
Retained Earnings	-8.9%	-1,011	-928	-849	-805	-764	-727	-672	-620	-570	-529	-493	-456	-420	-385	-331	-297	-276	-256	-158	-1.29
Additional Paid-In Capital	0.8%	863	856	831	823	675	652	646	614	608	602	597	589	585	580	488	486	485	484	6.00	0.00
Shares Outstanding	1.0%	59.00	58.00	57.00	57.00	44.00	41.00	38.00	38.00	38.00	31.00	37.00	37.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	526	-	-	-	198	-	-	-	684	-	-	-	552	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-57.6%	-69,020	-43,797	-31,914	-22,200	-39,669	-41,041	-35,016	-25,716	-44,757	-41,262	-29,066	-28,364	-49,765	-28,200	-20,727	-9,344	-11,417	-23,384	-7,108	-5,211	-807
Share Based Compensation	-77.1%	5,626	24,584	6,140	7,253	7,048	6,657	5,816	5,885	5,775	4,338	4,419	4,237	3,818	2,379	2,070	828	563	-	-	-	-
Cashflow From Investing	91.6%	-40.00	-475	-939	-6.00	-214	-412	-134	-428	-67.00	-100	-14.00	-45.00	-169	-124	-183	-57.00	-676	-	-	-	-
Cashflow From Financing	-95.3%	9,900	211,993	13.00	141,502	14,072	-	24,596	-	-	163	44,029	104	412	89,459	-	-	25,000	192,771	-1,299	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PHAT Income Statement

2024-03-31

Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Gross Profit [Abstract]
Product revenue, net	$ 1,912	$ 0
Cost of revenue	426	0
Gross profit	1,486	0
Operating expenses:
Research and development (includes related party amounts of $679 and $175, respectively)	9,430	11,479
Selling, general and administrative (includes related party amounts of $20 and $3, respectively)	62,010	18,598
Total operating expenses	71,440	30,077
Loss from operations	(69,954)	(30,077)
Other income (expense):
Interest income	4,313	1,460
Interest expense	(17,168)	(9,217)
Other (expense) income, net	(43)	20
Total other expense	(12,898)	(7,737)
Net loss and comprehensive loss	$ (82,852)	$ (37,814)
Net loss per share, basic	$ (1.42)	$ (0.89)
Net loss per share, diluted	$ (1.42)	$ (0.89)
Weighted-average shares of common stock outstanding, basic	58,371,480	42,354,520
Weighted-average shares of common stock outstanding, diluted	58,371,480	42,354,520

PHAT Balance Sheet

2024-03-31

Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 322,229	$ 381,393
Prepaid expenses and other current assets	12,748	13,194
Accounts receivable, net	3,879	1,637
Inventory	1,458	1,208
Total current assets	340,314	397,432
Property, plant and equipment, net	1,962	2,146
Operating lease right-of-use assets	1,264	1,475
Restricted cash	2,867	2,863
Inventory, noncurrent	8,400	8,234
Other long-term assets	1,692	1,692
Total assets	356,499	413,842
Current liabilities:
Accounts payable (including related party amounts of $33 and $25, respectively)	8,403	12,601
Accrued expenses (including related party amounts of $3,169 and $2,694, respectively)	16,541	17,197
Accrued interest	1,307	1,146
Operating lease liabilities, current	730	726
Current portion of revenue interest financing liability	16,478	7,111
Total current liabilities	43,459	38,781
Long-term debt, net of discount	149,023	137,842
Revenue interest financing liability	302,528	299,816
Operating lease liabilities	292	462
Other long-term liabilities	9,700	9,700
Total liabilities	505,002	486,601
Commitments and contingencies (Note 4)
Stockholders' deficit:
Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value; authorized shares - 400,000,000 at March 31, 2024 and December 31, 2023; issued and outstanding shares - 58,524,101 and 57,970,044 at March 31, 2024 and December 31, 2023, respectively	5	5
Treasury stock -19 shares at March 31, 2024 and December 31, 2023	0	0
Additional paid-in capital	863,029	855,921
Accumulated deficit	(1,011,537)	(928,685)
Total stockholders' deficit	(148,503)	(72,759)
Total liabilities and stockholders' deficit	$ 356,499	$ 413,842

About Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

CEO	Ms. Terrie J. Curran
WEBSITE	phathompharma.com
INDUSTRY	Biotechnology
EMPLOYEES	112

Phathom Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Phathom Pharmaceuticals Inc? What does PHAT stand for in stocks?

PHAT is the stock ticker symbol of Phathom Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Phathom Pharmaceuticals Inc (PHAT)?

As of Fri May 17 2024, market cap of Phathom Pharmaceuticals Inc is 618.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PHAT stock?

You can check PHAT's fair value in chart for subscribers.

What is the fair value of PHAT stock?

You can check PHAT's fair value in chart for subscribers. The fair value of Phathom Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Phathom Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PHAT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Phathom Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether PHAT is over valued or under valued. Whether Phathom Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Phathom Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PHAT.

What is Phathom Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PHAT's PE ratio (Price to Earnings) is -2.51 and Price to Sales (PS) ratio is 906.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PHAT PE ratio will change depending on the future growth rate expectations of investors.